Genetic Disorders Drug Market
Global Genetic Disorders Drug Market Size, Share and Trends Analysis Report, By Type (Single Gene Disorders, Chromosome Disorders, Multifactorial Disorders, and Others), By Application (Hospital and Clinics), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global genetic disorders drug market is anticipated to grow at considerable CAGR during the forecast year. A disease caused by a mutation in the DNA sequence is known as a genetic disorder. It is caused by a single gene mutation, numerous gene mutations, or a combination of gene mutations, environmental factors, and chromosome damage. The increasing prevalence of genetic abnormalities around the world is a primary factor driving the global genetic disorders drug market.
The increasing prevalence of genetic disorder around the world is a primary factor driving the global genetic disorders drug market. The Genetic and Rare Diseases Information Center (GARD) estimates that 25-30 million people in the US have a genetic condition. Furthermore, owing to FDA approvals, the global market for genetic diseases medications is expanding. For instance, in May 2019, AveXis Inc. reported that the US FDA had approved Zolgensma (onasemnogene abeparvovec-xioi). It is the first gene therapy to treat spinal muscular atrophy (SMA) in children under the age of two years.
Impact of COVID-19 on Global Genetic Disorders Drug Market
COVID-19 has impacted the global economy due to a slowdown in the manufacturing of various industries. The market for genetic disorders Drug is not affected during COVID-19, as it is a rare disease, and the distribution of the drugs was persistent due to pharmaceuticals being an essential commodity during COVID-19.
Segmental Outlook
The global genetic disorders drug market is segmented based on type and application. Based on type, the market is sub-segmented into single-gene disorders, chromosome disorders, multifactorial disorders, and others. Based on application, the market is sub-segmented into hospitals and clinics. Among these, the hospital end-users segment is expected to hold the major share in the global genetic disorders drug market due to the increasing number of patients diagnosed with genetic disorders in the hospitals.
Global Genetic Disorders Drug Market by End-users, 2021(%)
The Hospitals Segment is Anticipated to Hold a Major Share in the Global Genetic Disorders Drug market.
The hospital segment is expected to hold a major share in the global genetic disorders drug market due to the increasing cases of genetic disorders patients in the hospitals. Hospitals are the initial treatment center for most diseases. The rare diseases are mostly treated in hospitals for better efficacy. Thus, the increasing number of genetic disorders disease patients in the hospitals is increasing the demand for genetic disorders drugs in the hospitals for treatment. Resulting in the growth of the hospital’s segment among the global genetic disorders drug market.
Regional Outlooks
The global genetic disorders drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North American region is expected to hold the major share in the global genetic disorders drug market due to the presence of several key players in the region.
Global Genetic Disorders Drug Market Growth by Region, 2022-2028
The Asia Pacific Region is Anticipated to Hold a Prominent Share in the Global Genetic Disorders Drug Market During Forecast Year.
The Asia Pacific is anticipated to hold a prominent share in the market during the forecast year due to the increasing number of patients suffering from genetic disorders disease. According to United Nations Population Funds (UNFPA), the population of the Asia Pacific region is 60% of the world’s total population with around 4.3 billion people in the region. The Asia Pacific region has some of the most populous countries including India and China. This large population of the Asia Pacific region is expected to see an increase in genetic disorders disease patients. Thus, increasing the demand for genetic disorders drugs is resulting in the growth of the Asia Pacific region .
Market Players Outlook
The major companies serving the global genetic disorders drug market include AstraZeneca group Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, fundings, and new product launches. For instance, in June 2021, ProMetic Biotherapeutics Inc. announced the approval of Ryplazim (plasminogen, human-tvmh) from the US FDA. It is used to treat type 1 plasminogen deficiency, a disorder that can damage normal tissues and organ function and can lead to blindness.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global genetic disorders drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Genetic Disorder Drugs Market
• Recovery Scenario of Global Genetic Disorder Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. AstraZeneca group Co.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Eli Lilly and co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. F. Hoffmann-La Roche Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novartis International AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Pfizer Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Genetic Disorder Drugs Market by Type
4.1.1. Single Gene Disorders
4.1.2. Chromosome Disorders
4.1.3. Multifactorial Disorders
4.1.4. Others
4.2. Global Genetic Disorder Drugs Market by Application
4.2.1. Hospitals
4.2.2. Clinics
5. Regional Analysis
5.1. North America
5.1.1. The US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. Bristol Myers Squibb (BMS)
6.3. Corbus Pharmaceuticals, Inc.
6.4. GlaxoSmithKline plc
6.5. Idera Pharmaceuticals, Inc.
6.6. Merck Group
6.7. Neovacs
6.8. Octapharma AG
6.9. Takeda Pharmaceuticals Co. Ltd.
6.10. Viatris Inc.
1. GLOBAL GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL SINGLE-GENE DISORDERS IN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CHROMOSOME DISORDERS IN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL MULTIFACTORIAL DISORDERS IN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS IN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY AOLLICATION, 2021-2028 ($ MILLION)
7. GLOBAL GENETIC DISORDER DRUGS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL GENETIC DISORDER DRUGS IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY APLLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD GENETIC DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY APLLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL GENETIC DISORDER DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL GENETIC DISORDER DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL GENETIC DISORDER DRUGS MARKET, 2021-2028 (%)
4. GLOBAL GENETIC DISORDER DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL SINGLE GENE DISORDERS GENETIC DISORDER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CHROMOSOME DISORDERS GENETIC DISORDER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL MULTIFACTORIAL DISORDERS GENETIC DISORDER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHERS GENETIC DISORDER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL GENETIC DISORDER DRUGS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
10. GLOBAL GENETIC DISORDER DRUGS IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL GENETIC DISORDER DRUGS IN CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL GENETIC DISORDER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. US GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
14. CANADA GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. UK GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. FRANCE GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. GERMANY GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. ITALY GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. SPAIN GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. REST OF EUROPE GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. INDIA GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. CHINA GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. JAPAN GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. SOUTH KOREA GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF ASIA-PACIFIC GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD GENETIC DISORDER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
